278,822 Shares in DexCom, Inc. $DXCM Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 278,822 shares of the medical device company’s stock, valued at approximately $24,060,000. Mirae Asset Global Investments Co. Ltd. owned about 0.07% of DexCom as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of DXCM. Plato Investment Management Ltd acquired a new stake in DexCom during the 2nd quarter worth about $782,000. Aurora Investment Counsel bought a new position in shares of DexCom in the 2nd quarter worth about $2,340,000. Silvant Capital Management LLC acquired a new position in shares of DexCom in the 2nd quarter valued at about $5,359,000. E Fund Management Co. Ltd. acquired a new position in shares of DexCom in the 2nd quarter valued at about $1,273,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of DexCom in the 2nd quarter valued at about $89,940,000. 97.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. JPMorgan Chase & Co. upped their target price on DexCom from $82.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday. Weiss Ratings upgraded DexCom from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, October 6th. TD Cowen reiterated a “buy” rating and issued a $95.00 target price on shares of DexCom in a report on Friday, September 18th. Royal Bank Of Canada reissued an “outperform” rating and issued a $105.00 price target (up from $90.00) on shares of DexCom in a research note on Thursday, October 1st. Finally, Robert W. Baird set a $105.00 price target on DexCom and gave the stock an “outperform” rating in a report on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $95.50.

Trending Headlines about DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Canaccord Genuity Group raised its price target to $97 from $90 and upgraded DexCom to “buy,” implying approximately 14.4% upside from the referenced price. Canaccord Genuity Group recommendations
• Positive Sentiment: UBS raised its price target to $107 from $102 and maintained or assigned a “buy” view, representing approximately 26.2% potential upside. The higher target reflects confidence in DexCom’s growth prospects. UBS Group recommendations
• Positive Sentiment: DexCom exceeded third-quarter expectations, reporting adjusted earnings of $0.73 per share versus the $0.68 consensus estimate and revenue of approximately $1.34 billion versus $1.33 billion expected. Revenue grew 11.1% year over year, reinforcing the company’s operating momentum. DexCom third-quarter results presentation
• Positive Sentiment: Recent coverage points to improving patient access, clinical momentum, and new product launches as factors supporting DexCom’s longer-term growth trajectory. DexCom improving patient access article
• Neutral Sentiment: Additional reports cited analyst price targets ranging from $85 to $120, indicating a generally constructive but varied view of DexCom’s valuation and upside potential. DexCom price target report

Insider Transactions at DexCom

In other news, EVP Jereme M. Sylvain sold 3,638 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $83.27, for a total transaction of $302,936.26. Following the transaction, the executive vice president directly owned 146,828 shares of the company’s stock, valued at $12,226,367.56. This represents a 2.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Brown sold 1,700 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $85.48, for a total value of $145,316.00. Following the completion of the transaction, the executive vice president owned 98,185 shares in the company, valued at approximately $8,392,853.80. This represents a 1.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 22,822 shares of company stock valued at $1,920,193 over the last ninety days. Company insiders own 0.28% of the company’s stock.

DexCom Stock Up 3.0%

DXCM stock opened at $84.76 on Tuesday. The stock’s 50 day simple moving average is $85.67 and its 200 day simple moving average is $74.73. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $92.59. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. The company has a market cap of $31.99 billion, a P/E ratio of 33.24, a price-to-earnings-growth ratio of 1.32 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, October 29th. The medical device company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.05. DexCom had a return on equity of 35.94% and a net margin of 20.12%. The business had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.33 billion. During the same quarter in the prior year, the company earned $0.61 earnings per share. The company’s quarterly revenue was up 11.1% on a year-over-year basis. On average, research analysts expect that DexCom, Inc. will post 2.67 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.